ALKS
Alkermes plc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 29 to Jun 4 ▼ 3 days of insider sells: $1.1M by 3 insiders, avg $42.19
- Jun 12 ▼ 1 insider sell $90.2K at $45.10
- Jun 29 ▼ B of A Securities downgrades
- Jul 1 to Jul 6 ▼ 2 days of insider sells: $573.5K by 2 insiders, avg $51.98
- Aug 3 ▼ 3 insiders sell $2.8M at $50.00
- Aug 17 ▼ 1 insider sell $372.9K at $49.23
- Sep 1 to Sep 3 ▼ 2 days of insider sells: $520.5K by 2 insiders, avg $47.17
- Sep 21 ▲ Alkermes announced positive Phase 1b proof-of-concept data for ALKS…
- Sep 30 ▲ 4 funds open new positions (13F)
- Oct 2 ▼ 1 insider sell $83.5K at $41.03
- Nov 3 ▲ Earnings: ALKS Q3 2026 Earnings: EPS $0.09 (+225.0% vs est)
- Nov 3 ▼ 1 insider sell $94.0K at $46.17
Signal stack
Where each data set points today.
- InsidersBEARISH
6 insiders sold $5.7M.
- InstitutionsBULLISH
Q3 2026: 44 added (4 new), 19 trimmed or exited. Largest new: Capital World Investors $19.2M, Qube Research & Technologies $15.2M.
- AnalystsBULLISH
20 of 27 rate it Buy or better. Median target $60.00 (+29%).
- Short sellersSTEADY
Short interest +3.1% to 19.65M shares. 11.3 days to cover, ≈11.7% of shares.
- TrendUPTREND
7% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| AMERICAN CENTURY COMPANIES INC | TRIM | $61.1M |
| Invesco Ltd. | DOUBLED | $59.4M |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | ADD | $43.2M |
| Artisan Partners Limited Partnership | TRIM | $23.3M |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | DOUBLED | $21.6M |
| Capital World Investors | NEW | $19.2M |
| UBS Group AG | ADD | $18.8M |
| Qube Research & Technologies Ltd | NEW | $15.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
27 analystsPrice is inside the target range. Median implies +29%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 4, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 4, 2026 | Wells Fargo MAINTAIN | Overweight |
| Nov 4, 2026 | HC Wainwright & Co. MAINTAIN | Neutral |
| Sep 22, 2026 | RBC Capital REITERATE | Outperform |
| Sep 22, 2026 | Baird MAINTAIN | Outperform |
| Sep 21, 2026 | Needham REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Nov 3, 2026 | SELL | $94.0K |
Reed Joshua SVP, Chief Financial Officer Oct 8, 2026 | EXERCISE | 9,164 sh |
Reed Joshua SVP, Chief Financial Officer Oct 8, 2026 | TAX W/H | $163.2K |
Whitaker Anne Clem Director Oct 7, 2026 | AWARD | 17,998 sh |
Whitaker Anne Clem Director Oct 7, 2026 | AWARD | 7,239 sh |
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Oct 2, 2026 | SELL | $83.5K |
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Sep 3, 2026 | SELL | $97.7K |
Hopkinson Craig C. EVP R&D, Chief Medical Officer Sep 1, 2026 | EXERCISE | $123.0K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
23 filings · 2 bullish · 2 bearish · 2 mixed · 17 neutral- NEUTRAL 8-KNov 12, 2026
Alkermes settled a patent infringement lawsuit with Teva over LYBALVI (olanzapine/samidorphan)…
The settlement removes litigation overhang and secures LYBALVI exclusivity until at least late 2039. Monitor FTC/DOJ review and any potential earlier entry triggers. No immediate revenue impact, but…
- NEUTRAL INST-CLUSTERNov 4, 2026
Three institutional investors (Strs Ohio, Mackenzie Financial, Allspring Global Investments)…
The cluster is small and dominated by asset managers with modest dollar amounts; the net selling by Citigroup outweighs the buying. The 13F data is 45+ days stale and may already be unwound. Monitor…
- NEUTRAL 144Nov 3, 2026
David Gaffin, an officer of Alkermes, filed a Form 144 notice of intent to sell 2,035 shares of…
The sale is small and consistent with prior periodic sales by this officer. No material signal for the stock. Monitor for any change in pattern or larger insider sales.
- NEUTRAL 8-KNov 3, 2026
Alkermes reported Q3 2026 total revenue of $480.1M, up 21.8% YoY from $394.2M, driven by LUMRYZ…
Revenue beat consensus but EPS missed, with GAAP net income declining sharply YoY due to acquisition-related costs and higher R&D spending. The reiterated guidance provides no catalyst; watch for…
All ALKS filing & press-release reports (23)
- 8-K reportNov 12, 2026
- INST-CLUSTER reportNov 4, 2026
- 144 reportNov 3, 2026
- 8-K reportNov 3, 2026
- 8-K reportSep 21, 2026
- 8-K reportSep 16, 2026
- CLUSTER reportSep 3, 2026
- CLUSTER reportAug 3, 2026
- CLUSTER reportAug 3, 2026
- CLUSTER reportAug 3, 2026
- 8-K reportJul 28, 2026
- 8-K reportJul 8, 2026
- CLUSTER reportJul 6, 2026
- CLUSTER reportJun 4, 2026
- CLUSTER reportJun 1, 2026
- 8-K reportMay 20, 2026
- DEFA14A reportMay 13, 2026
- 8-K reportMay 12, 2026
- 8-K reportMay 5, 2026
- CLUSTER reportMay 1, 2026
- CLUSTER reportMar 2, 2026
- 8-K reportFeb 25, 2026
- 8-K reportFeb 25, 2026